Direkt zum Inhalt
Merck

CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells.

Biochemical and biophysical research communications (2015-06-24)
Kaori Kubo, Masashi Iwakami, Ryuta Muromoto, Takuya Inagaki, Yuichi Kitai, Shigeyuki Kon, Yuichi Sekine, Kenji Oritani, Tadashi Matsuda
ZUSAMMENFASSUNG

Chronic myeloid leukemia is a clonal disease characterized by the presence of the Philadelphia chromosome and its oncogenic product, BCR-ABL, which activates multiple pathways involved in cell survival, growth promotion, and disease progression. We previously reported that in murine hematopoietic Ba/F3 cells, signal transducing adaptor protein-2 (STAP-2) binds to BCR-ABL and up-regulates BCR-ABL phosphorylation, leading to enhanced activation of its downstream signaling molecules. The binding of STAP-2 to BCR-ABL also influenced the expression levels of chemokine receptors, such as CXCR4 and CCR7. For the induction of CCR7 expression, signals mediated by the MAPK/ERK pathway were critical in Ba/F3 cells expressing BCR-ABL and STAP-2. In addition, STAP-2 cooperated with BCR-ABL to induce the production of CCR7 ligands, CCL19 and CCL21. Our results demonstrate a contribution of CCR7 to STAP-2-dependent enhancement of BCR-ABL-mediated cell growth in Ba/F3 cells.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Laurinsäure, ≥98%, FCC, FG
Sigma-Aldrich
Laurinsäure, 98%
Sigma-Aldrich
Laurinsäure, natural, ≥98%, FCC, FG
Sigma-Aldrich
Dodecansäure, ≥99% (GC/titration)
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Ccr7
Sigma-Aldrich
MISSION® esiRNA, targeting human CCR7